MORE THAN JUST PATIENT’S
European association taking the interests of European pALS
EupALS is an European association taking the interests of European pALS (ALS patients) to heart. We thus want to create equal rights for all the European pALS and provide better access to research and information about it.
Subscribe to our newsletter
NEWS
-
EMA announcement positive CHMP opinion for Biogen Tofersen (Qualsody)
23 February 2024 New treatment for rare motor neurone disease recommended for approval EMA has recommended granting a marketing authorisation in the European Union for a new therapy for the… More >>
-
EUpALS in Lancet Neurology editorial November 2023
Speeding up research to improve the lives of people with ALS Advances in research over the past few years have provided a greater understanding of the pathophysiology, genetics, and risk… More >>
MISSION
Aiming to unite all the European ALS associations…
… to fight harder together on a European scale
Stand up for the rights of all the European pALS
Create awareness on a European scale
Improve access to & information about research
Create the same rules for ALS research across Europe
ALS RESEARCH NEWS
Checkout the most recent Articles And Insights on ALS Research
-
VectorY Therapeutics Announces First Participant Dosed in Phase 1/2 PIONEER-ALS Clinical Trial of VTx-002 in People with ALS
February 9, 2026 VTx-002 is a first-in-class vectorized antibody to holistically target TDP-43 pathology in ALS recently granted FDA Fast Track Designation for expedited review VectorY Therapeutics, a leader in… More >>
-
VectorY Therapeutics Receives FDA Clearance of IND to Proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002, a First-in-Class Vectorized Antibody Targeting TDP-43 Pathology in ALS
VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced that the U.S. Food and Drug Administration (FDA) has cleared the company to proceed with the PIONEER-ALS Phase… More >>
-
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
NeuroSense Therapeutics, a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, announced that the U.S. Food and Drug Administration (FDA) has completed the review of the Investigational… More >>
-
Collaborative Partnership between IQVIA and TRICALS
Amyotrophic Lateral Sclerosis (ALS), also known as motor neurone disease (MND) or Lou Gehrig’s Disease (LGD) in the US, is a progressive neurodegenerative disease. Although relatively rare, with 2 new… More >>